This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2018 Jan 11;378(2):195.

doi: 10.1056/NEJMc1714810.

Romosozumab versus Alendronate and Fracture Risk in Women with Osteoporosis

Elena Tsourdi¹, Tilman D Rachner¹, Lorenz C Hofbauer¹

Affiliations

PMID: 29322753
DOI: 10.1056/NEJMc1714810

Comment

Romosozumab versus Alendronate and Fracture Risk in Women with Osteoporosis

Elena Tsourdi et al. N Engl J Med. 2018.

. 2018 Jan 11;378(2):195.

doi: 10.1056/NEJMc1714810.

Authors

Elena Tsourdi¹, Tilman D Rachner¹, Lorenz C Hofbauer¹

Affiliation

¹ Technische Universität Dresden, Dresden, Germany lorenz.hofbauer@uniklinikum-dresden.de

PMID: 29322753
DOI: 10.1056/NEJMc1714810

No abstract available

PubMed Disclaimer

Comment in

Romosozumab versus Alendronate and Fracture Risk in Women with Osteoporosis.
Saag KG, Petersen J, Grauer A. Saag KG, et al. N Engl J Med. 2018 Jan 11;378(2):195-196. doi: 10.1056/NEJMc1714810. N Engl J Med. 2018. PMID: 29320649 No abstract available.

Comment on

Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.
Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A. Saag KG, et al. N Engl J Med. 2017 Oct 12;377(15):1417-1427. doi: 10.1056/NEJMoa1708322. Epub 2017 Sep 11. N Engl J Med. 2017. PMID: 28892457 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Other Literature Sources
- scite Smart Citations